Effects of various adjuvants and a viral infection on the antibody specificity toward native or cryptic epitopes of a protein antigen.
An immunization protocol that induces antibodies (Abs) directed to cryptic epitopes of a protein antigen (Ag) reduces the efficacy of vaccines that ideally should induce Abs against native epitopes. We have shown earlier that viral infections concomitant with immunization against a protein tend to shift the Ab specificity toward cryptic epitopes and tend to induce the production of autoantibodies (autoAbs). Here, we show the effects of three adjuvants on the Ab specificity in the absence or presence of a viral infection (lactate dehydrogenase-elevating virus or LDV), with human growth hormone (hGH) being, as before, the protein Ag. Pathogen-free CBA/Ht and BALB/c mice were immunized with hGH in the presence of complete Freund's adjuvant (CFA), monophosphoryl lipid A (MPL) or alum, with the animals being either infected with LDV or not infected with LDV. Conventional and competition enzyme-linked immunosorbent assays (ELISAs) indicated that in noninfected mice, CFA induced higher titres of anti-hGH Ab than did MPL or alum, with the Ab being almost totally directed to cryptic hGH epitopes. Strikingly, CFA plus LDV infection in CBA/Ht mice shifted the specificity of the anti-hGH Ab toward native epitopes, whereas the virus decreased the Ab titre when MPL or alum was used. Our Western blot results showed that 70% of mice immunized with hGH in the presence of any adjuvant produced autoAbs against a variety of tissue Ags. The amount of autoAb and the concentration of Ab to hGH cryptic epitopes did correlate, suggesting a relationship between both kinds of Ab. Significant differences were observed in the various effects of adjuvants and the viral infection between the two mouse strains used in this work.
Gómez
K A
KA
Instituto de Química y Fisicoquímica Biológicas (UBA-CONICET), Facultad de Farmacia y Bioquímica, Buenos Aires, Argentina.
Longhi
S A
SA
Marino
V J
VJ
Mathieu
P A
PA
Loureiro
M E
ME
Coutelier
J-P
JP
Roguin
L P
LP
Retegui
L A
LA
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000534:Alum Compounds / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D000918:Antibody Specificity / Q000276:immunology*; D018174:Arterivirus Infections / Q000276:immunology*; D001323:Autoantibodies / Q000096:biosynthesis; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology* / Q000378:metabolism; D005260:Female; D005620:Freund's Adjuvant / Q000494:pharmacology; D019382:Human Growth Hormone / Q000276:immunology*; D007668:Kidney / Q000276:immunology; D007772:Lactate dehydrogenase-elevating virus / Q000276:immunology*; D008050:Lipid A / Q000031:analogs & derivatives* / Q000494:pharmacology; D008099:Liver / Q000276:immunology; D051379:Mice; D008807:Mice, Inbred BALB C; D008808:Mice, Inbred CBA; D009132:Muscles / Q000276:immunology; D009206:Myocardium / Q000276:immunology
D000276:Adjuvants, Immunologic; D000534:Alum Compounds; D000914:Antibodies, Viral; D001323:Autoantibodies; D000939:Epitopes; D008050:Lipid A; D019382:Human Growth Hormone; C041524:aluminum sulfate; D005620:Freund's Adjuvant; C048436:monophosphoryl lipid A